Semaglutide vs. Tirzepatide — Who Wins the Weight Loss Battle?
Get pre-approved for weight loss medication like Zepbound® (tirzepatide) with our 3-minute online assessment.
The FDA does not approve compounded drugs or verify their safety,
effectiveness, or quality. Prescription products require an online
clinician visit.
1 2 3 4
How do you want to lose weight?
Easy, weekly medication Personalized Nutrition All of the above1 2 3 4
Are you looking to skip waiting rooms and pharmacy lines?
All online, please! Doesn’t matter1 2 3 4
Are you looking for doctor-trusted weight loss medication?
(That’s the only kind we have)
Yes, please I am not sureGood News!
We have the meds that you need.
- Lose up to 1.5% of your body fat per week*
- Get access to Zepbound®, (trizepatide) and other great GLP-1 + GIP weight loss medications
- Get approved with this 3-min quiz, no insurance needed
* Participants achieved additional 6.7% weight loss following a
36-week open-label lead-in period, for a total mean weight loss of
26.0% from study entry over 88 weeks. See details. Results may vary
based on starting weight and program adherence. Medication
prescriptions are at the discretion of medical providers and may
not be suitable for everyone. Consult a healthcare professional
before starting any weight loss program.
**During a 68-week trial 1 in 3 users reached a 20% body weight reduction while on semaglutide.
**Users on a 2.4mg semaglutide injection were shown to have a reduction in waist measurements up to 13cm.
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183
Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity. See details. Results may vary based on starting weight and program adherence. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Consult a healthcare professional before starting any weight loss program.
**During a 68-week trial 1 in 3 users reached a 20% body weight reduction while on semaglutide.
**Users on a 2.4mg semaglutide injection were shown to have a reduction in waist measurements up to 13cm.
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183
Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity. See details. Results may vary based on starting weight and program adherence. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Consult a healthcare professional before starting any weight loss program.